Last updated on April 2018

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL


Brief description of study

A prospective, open-label, multicentre phase-II trial of ibrutinib plus venetoclax plus obinutuzumab in physically fit (CIRS 6 & normal creatinine clearance) and unfit (CIRS > 6 & creatinine clearance 50 ml/min) patients with previously untreated chronic lymphocytic leukemia (CLL) with TP53 deletion (17p-) and/or mutation

Detailed Study Description

Chronic lymphocytic leukemia (CLL) with TP53 deletion (17p-) and/or mutation has a poor prognosis. Different therapeutic strategies have been tested over the last decade such as fludarabine-based regimens, alemtuzumab, bendamustine alone or with rituximab, lenalidomide, or ofatumumab, but all without compelling evidence for success. For example, with the FCR regimen as the standard 1st line treatment for fit CLL patients, only 5% (1 of 22) of patients with 17p deletion had a complete response (CR) and 40% of patients were free of disease progression at 12 months in the CLL8 Trial. New agents like Bruton's Tyrosin Kinase (BTK) inhibitors such as ibrutinib have shown promising results in patients with relapsed or refractory CLL, however, outcome of CLL patients with 17p deletion is inferior to other subgroups. The CLL11 trial revealed an impressive improvement in efficacy with GA-101 (obinutuzumab) as compared to rituximab when combined with Chlorambucil. Moreover, the BCL2 antagonist venetoclax (previously GDC-0199/ABT-199), tested as a single agent in relapsed / refractory CLL patients, showed striking activity with tumor lysis syndrome as dose limiting toxicity. Consequently, the current trial will test a combination regimen consisting of obinutuzumab, ibrutinib and venetoclax (the "GIVe" regimen) as first line treatment in CLL patients with TP53 deletion (17p-) and/or mutation with the aim to demonstrate efficacy in this population at highest unmet medical need.

The primary objective of the study is to evaluate the efficacy of the GIVe regimen in patients with TP53 deletion (17p-) and/or mutation and previously untreated CLL requiring treatment.

For this, the CR rate at cycle 15 (d1; final restaging) will be used as primary parameter for efficacy. The CR rate is defined as the proportion of patients having achieved a CR or a CR with incomplete recovery of the bone marrow (CRi) as best response (according to iwCLL criteria) until cycle 15 (d1; final restaging) from start of therapy.

Efficacy of the regimen will be further assessed by evaluation of the proportion of patients free of disease progression (PD-free rate) after 12 cycles of therapy, overall response rate (ORR), minimal residual disease (MRD) and overall survival as well as other time to event endpoints as outlined below.

A further secondary objective of the study is to evaluate the safety of ibrutinib, venetoclax and obinutuzumab.

Clinical Study Identifier: NCT02758665

Contact Investigators or Research Sites near you

Start Over

Jan Duerig, MD

Universit tsklinikum Essen
Essen, Germany
  Connect »

Rainer Claus, MD

Universit tsklinikum Freiburg
Freiburg, Germany
  Connect »

Peter Dreger, MD

Universit tsklinikum Heidelberg
Heidelberg, Germany
  Connect »

Michael Pfreundschuh, MD

Universit tsklinikum des Saarlandes
Homburg / Saar, Germany
  Connect »

Sebastian Boetcher, MD

Universit tsklinikum Schleswig-Holstein
Kiel, Germany
  Connect »

Georg Heß, MD

Universit tsmedizin der Johannes Gutenberg-Universit t Mainz
Mainz, Germany
  Connect »

Stephan Stilgenbauer, MD

Universit tsklinikum Ulm
Ulm, Germany
  Connect »

Lutz Jacobasch

BAG Onkologische Gemeinschaftspraxis
Dresden, Germany
  Connect »

Michael Hallek, MD

Universit tsklinikum K ln
Köln, Germany
  Connect »

Manuela Bergmann, MD

Klinikum Schwabing
München, Germany
  Connect »